FILE PHOTO: U.S. President Donald Trump talks with Canada’s Prime Minister Justin Trudeau during a North Atlantic Treaty Organization Plenary Session at the NATO summit in Watford, Britain, December 4, 2019. REUTERS/Kevin Lamarque/File Photo
November 28, 2020
By Steve Scherer
OTTAWA (Reuters) – Canada on Saturday blocked bulk exports of prescription drugs if they would create a shortage at home, in response to outgoing U.S. President Donald Trump’s efforts to allow imports from Canada to lower some drug prices for Americans.
“Certain drugs intended for the Canadian market are prohibited from being distributed for consumption outside of Canada if that sale would cause or worsen a drug shortage,” Health Minister Patty Hajdu said in a statement.
“Companies will now also be required to provide information to assess existing or potential shortages, when requested, and within 24 hours if there is a serious or imminent health risk,” the statement said.
The Canadian measure went into effect on Friday, just days before a U.S. “Importation Prescription Drugs” rule that would eventually allow licensed U.S. pharmacists or wholesalers to import in bulk certain prescription drugs intended for the Canadian market.
Neither the White House nor the Department of Health and Human Services had an immediate response to a request for comment.
Trump touted the plan in his first debate with President-elect Joe Biden, who has also said during his campaign that he would set up a similar import plan to try to reduce prescription drug costs for Americans.
“Canada is a small market, representing 2% of global drug sales, that sources 68% of its drugs internationally. The need for vigilance in maintaining the national drug supply continues,” the statement said.
Canadian Prime Minister Justin Trudeau said in September he was willing to help other nations with pharmaceutical supplies if possible, adding that his priority was protecting the needs of Canadians.
Many of Canada’s drug suppliers opposed Trump’s plan, saying it could lead to shortages.
(Reporting by Steve Scherer, additional reporting by Alexandra Alper in Washington; Editing by Nick Zieminski)
